Gustavo Lopardo

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Marta Francesca Di Pasquale, Giovanni Sotgiu, Andrea Gramegna et al. · Clinical Infectious Diseases · 2018 · 256 citations · Full text

Medicine, Immunology, Infectious Diseases +12

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 237 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Thomas M. File, Donald E. Low, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 196 citations · Full text

Medicine, Infectious Diseases, Pharmacology +13

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

Stefano Aliberti, Luis Felipe Reyes, Paola Faverio et al. · The Lancet Infectious Diseases · 2016 · 175 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16